Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer

Table 1

The characteristics of the analyzed patients in different groups.

Characteristics					value
		%		%
No. patients	81		56
Gender (%)
Male	59	72.8%	39	69.6%	0.685
Female	22	27.2%	17	30.4%
(%)
<59	35	43.2%	21	37.5%	0.505
≥59	46	56.8%	35	62.5%
PD-L1 (%)
Positive	14	17.3%	11	19.6%	0.227
Negative	14	17.3%	15	26.8%
Unknown	53	65.4%	30	53.6%
ECOG PS (%)
0	26	32.1%	10	17.9%	0.508
1	43	53.1%	43	76.8%
≥2	12	14.8%	3	5.4%
Tumor_location (%)
Cardia	25	30.9%	14	25.0%	0.448
Body/fundus	50	61.7%	37	66.1%
Pylorus	6	7.4%	5	8.9%
Histological_differentiation (%)
Poorly	40	49.4%	31	55.4%	0.473
Moderately	37	45.7%	23	41.1%
Well	4	4.9%	2	3.6%
No. of metastasis organs (%)
<2	24	29.6%	11	19.6%	0.189
≥2	57	70.4%	45	80.4%
Liver metastasis (%)
Yes	49	60.5%	31	55.4%	0.55
No	32	39.5%	25	44.6%
Smoking_history (%)
Smoke	30	37.0%	29	51.8%	0.088
Never smoked	51	63.0%	27	48.2%
Drinking_history (%)
Drink	38	46.9%	35	62.5%	0.073
Never drinked	43	53.1%	21	37.5%
Anti-PD-1 treatment line (%)
First line	42	51.9%	24	42.9%	0.421
Second line	34	42.0%	30	53.6%
Third line	5	6.2%	2	3.6%
Treatment type (%)
Anti-PD-1 monotherapy	8	9.9%	7	12.5%	0.741
Combination therapy
Anti-PD-1 plus chemotherapy	55	67.9%	37	66.1%
Anti-PD-1 plus antiangiogenic therapy	18	22.2%	12	21.4%

ECOG PS: Eastern Cooperative Oncology Group Performance Status; PD-L1: programmed death ligand-1.